Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Stephen_R._Davis
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:pimavanserin
|
| gptkbp:focusesOn |
central nervous system disorders
|
| gptkbp:foundedIn |
1993
|
| gptkbp:founder |
Mark R. Brann
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Acadia Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:marketedAs |
NUPLAZID
|
| gptkbp:notableProduct |
NUPLAZID
|
| gptkbp:numberOfEmployees |
over 500
|
| gptkbp:NUPLAZIDIndication |
Parkinson's disease psychosis
|
| gptkbp:pipelineProduct |
ACP-044
ACP-319 trofinetide |
| gptkbp:publiclyTraded |
gptkb:NASDAQ
|
| gptkbp:researchInterest |
neurology
psychiatry |
| gptkbp:specializesIn |
orphan drugs
rare diseases |
| gptkbp:stockSymbol |
ACAD
|
| gptkbp:website |
https://www.acadia-pharm.com/
|
| gptkbp:bfsParent |
gptkb:ACH-3102
gptkb:pimavanserin |
| gptkbp:bfsLayer |
8
|